

Table S1 Literature review of complete pathological response after tyrosine kinase inhibitor (TKI)

Case	Reference	cTNM	TKI	Length of preoperative treatment (months)	Length of postoperative treatment (months)
1	Zhang <i>et al.</i> (<i>J Thorac Oncol</i> , 2019) (17)	cT2aN2M0	Crizotinib	3	4
2	Zhang <i>et al.</i> (<i>J Thorac Oncol</i> , 2019) (17)	cT2bN2M0	Crizotinib	2.3	3.6
3	Rotow <i>et al.</i> (<i>Clin Lung Cancer</i> , 2019) (18)	cT1bN2M0	Crizotinib	8	6
4	Zhai <i>et al.</i> (<i>Front Oncol</i> , 2023) (19)	cT1cN3M0	Crizotinib	5	36
5	Zhang <i>et al.</i> (<i>J Thorac Oncol</i> , 2019) (20)	NA	Crizotinib	2	3.6
6	Shen <i>et al.</i> (<i>Chin Med J</i> , 2023) (21)	cT2aN2M0	Ceritinib	7	0
7	Sentana-Lledo <i>et al.</i> (<i>Lung Cancer</i> , 2022) (22)	cT1bN2M0	Alectinib	1.5	3
8	Hu <i>et al.</i> (<i>Front Pharmacol</i> , 2022) (23)	cT2bN2M0	Alectinib	2	8
9	Shi <i>et al.</i> (<i>Front Oncol</i> , 2023) (24)	cT3N0M0	Alectinib	7.5	13
10	Shi <i>et al.</i> (<i>Front Oncol</i> , 2023) (24)	cT3N0M0	Alectinib	8	12
11	Wang <i>et al.</i> (<i>World J Clin Cases</i> , 2023) (25)	cT2aN3M0	Alectinib	14	29
12	Lococo <i>et al.</i> (<i>Clin Lung Cancer</i> , 2023) (9)	cT3N2M0	Alectinib	7.1	13
13	Lococo <i>et al.</i> (<i>Clin Lung Cancer</i> , 2023) (9)	cT4N2M0	Alectinib	6.5	11
14	Lococo <i>et al.</i> (<i>Clin Lung Cancer</i> , 2023) (9)	cT3N2M0	Alectinib	10.3	0
15	Lococo <i>et al.</i> (<i>Clin Lung Cancer</i> , 2023) (9)	cT4N2M0	Alectinib	1.4	4
16	Lococo <i>et al.</i> (<i>Clin Lung Cancer</i> , 2023) (9)	cT3N2M0	Alectinib	6	5
17	Chen <i>et al.</i> (<i>Heliyon</i> , 2023) (26)	cT1bN2M0	Lorlatinib	2	11
18	Lu <i>et al.</i> (<i>Transl Lung Cancer Res</i> , 2024) (27)	cT2bN2M0	Lorlatinib	3	10
19	Seong <i>et al.</i> (<i>Font Oncol</i> , 2024) (28)	cT3N1M0	Brigatinib	2	13

References

17. Zhang C, Li SL, Nie Q, et al. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement. *J Thorac Oncol* 2019;14:726-31.
18. Rotow JK, Woodard GA, Urisman A, et al. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. *Clin Lung Cancer* 2019;20:e137-41.
19. Zhai X, Wang T, Lin Y, et al. Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib. *Front Oncol* 2023;13:1104910.
20. Zhang C, Wu YL, Zhong WZ. Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib. *J Thorac Oncol* 2019;14:e234-6.
21. Shen Q, Gao Q, Zhou J. Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer. *Chin Med J (Engl)* 2023;136:851-3.
22. Sentana-Lledo D, Viray H, Piper-Vallillo AJ, et al. Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer. *Lung Cancer* 2022;172:124-6.
23. Hu Y, Ren S, Wang R, et al. Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer. *Front Pharmacol* 2022;13:816683.
24. Shi L, Gao S, Tong L, et al. Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports. *Front Oncol* 2023;13:1120511.
25. Wang LM, Zhao P, Sun XQ, et al. Pathological complete

- response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report. *World J Clin Cases* 2023;11:5322-8.
26. Chen R, Zhao L, Zhang J, et al. Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report. *Heliyon* 2023;9:e21582.
27. Lu L, Cao Z, Wang A, et al. Pathological complete response to neoadjuvant lorlatinib in a patient with stage IIIA ALK-positive non-small cell lung cancer: a case report. *Transl Lung Cancer Res* 2024;13:1742-8.
28. Seong H, Kim SH, Kim MH, et al. Case report: Pathological complete response to neoadjuvant brigatinib in stage III non-small cell lung cancer with ALK rearrangement. *Front Oncol* 2024;14:1343238.